Brown Advisory Inc. Has $90.36 Million Holdings in Catalent Inc (CTLT)
Brown Advisory Inc. grew its position in Catalent Inc (NYSE:CTLT) by 4.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,156,976 shares of the company’s stock after purchasing an additional 91,445 shares during the period. Brown Advisory Inc.’s holdings in Catalent were worth $90,356,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of CTLT. Champlain Investment Partners LLC raised its holdings in Catalent by 19.2% in the first quarter. Champlain Investment Partners LLC now owns 3,627,390 shares of the company’s stock worth $148,941,000 after purchasing an additional 583,675 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Catalent by 59.8% during the first quarter. Wells Fargo & Company MN now owns 1,146,493 shares of the company’s stock worth $47,074,000 after acquiring an additional 429,061 shares during the period. Prudential Financial Inc. raised its holdings in shares of Catalent by 48.0% during the first quarter. Prudential Financial Inc. now owns 1,041,568 shares of the company’s stock worth $42,767,000 after acquiring an additional 337,828 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Catalent by 4.3% during the second quarter. Janus Henderson Group PLC now owns 6,400,737 shares of the company’s stock worth $268,127,000 after acquiring an additional 266,183 shares during the period. Finally, GW&K Investment Management LLC raised its holdings in shares of Catalent by 16.1% during the first quarter. GW&K Investment Management LLC now owns 1,903,864 shares of the company’s stock worth $78,173,000 after acquiring an additional 263,963 shares during the period. Institutional investors own 98.76% of the company’s stock.
CTLT has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a report on Thursday, May 10th. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, June 5th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $46.00.
In other Catalent news, SVP Steven L. Fasman sold 2,252 shares of Catalent stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $41.78, for a total value of $94,088.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.70% of the stock is currently owned by insiders.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Featured Article: How to Use the New Google Finance Tool
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.